Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
